1. A glimpse to the future: The ARV pipeline up to how do we ensure it is affordable and acceptable?
Helen McDowell
Head of Government Affairs & Global Public Health
24 July 2018 AIDS 2018

2. Conflicts of interest
I am a full time permanent employee of ViiV Healthcare and hold shares in GlaxoSmithKline (majority shareholder of ViiV Healthcare)

3. Community insights drive our efforts
We listen and engage with people living with HIV and use these insights to inform and drive everything we do

4. No one should take more medicine than they need
Reducing long term effect of HIV medication on the body ranked as the most important improvement among PLHIV
72%
PLHIV worry about long-term effects of HIV treatments
56%
PLHIV would consider reducing the number of drugs in their regimen to the minimum
Positive Perspectives Survey, presented at EACS 2017

5. Investing in innovative R&D to benefit PLHIV
Our focus areas have the potential to change the way we treat HIV with the goal to reduce long-term toxicities
Small molecule ARVs
Biologic (monoclonal antibody) ARVs
Alternative methods of delivery (e.g. long-acting injectables)
Simplified regimens with improved long-term outcomes
Maturation inhibitor as possible addition to arsenal of treatment options
Attachment inhibitor for heavily treatment-experienced patients
Ensure what we do helps PLHIV
Involve
PLHIV in process
PLHIV benefit from our R&D efforts

6. Our pipeline makes a difference to PLHIV
Pipeline strategy
Long-acting Treatment Regimens
cabotegravir + rilpivirine*
Prevention
cabotegravir long-acting*
Search for
Remission and Cure
Legacy ARV Drug Portfolio
abacavir/lamivudine,
maraviroc & others
Dolutegravir-based Regimens
Tivicay
Triumeq
Two Drug Regimens
dolutegravir/rilpivirine*
dolutegravir/lamivudine*
New MOA
attachment inhibitor (fostemsavir)*
Combinectin (GSK )*ǂ
maturation inhibitor portfolio*ǂ
allosteric integrase inhibitor *ǂ
capsid inhibitor*ǂ
New treatment paradigm = 2DR
Current standard of care = HAART/legacy drugs
*investigational treatments
ǂDiscovery program

7. Enabling global access and uptake: Collaboration is key
Research and Development and
Product Registration
Patents and Voluntary Licensing
Flexible Pricing and Local Manufacturing
Healthcare and Community Capacity Building